Expanding the spectrum of white matter abnormalities in Wolfram syndrome: A retrospective review

- 1 Justin Simo, BSc^{1,2}, Heather M. Lugar, MA³, Elka Miller, MD⁴, Adi Wilf-Yarkoni, MD, MSc^{5,6},
- 2 Yael Goldberg, MD^{6,7}, Ayça Kocaağa, MD⁸, Shoichi Ito, MD, PhD⁹, Sirio Cocozza, MD, PhD¹⁰,
- 3 Giulio Frontino, MD, MSc¹¹, Cristina Baldoli, MD¹², Aziz Benbachir^{1,2}, Catherine Ashton,
- 4 MBBS^{1,2,13}, Guy Rouleau, MD, PhD^{1,2,14}, Tamara Hershey, PhD^{3,15}, Yann Nadjar, MD, PhD¹⁶,
- 5 Roberta La Piana, MD, PhD^{1,2,17}
- ⁶ ¹ The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada
- ⁷ ² Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
- 8 ³ Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
- ⁹ ⁴ Department of Diagnostic Imaging, The Hospital for Sick Children (SickKids), University of
- 10 Toronto, Toronto, ON, Canada
- ⁵ Neuroimmunology Unit, Rabin Medical Center—Beilinson Hospital, Petach Tikva, Israel
- ⁶ Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- ⁷ The Raphael Recanati Genetic Institute, Rabin Medical Center—Beilinson Hospital, Petach Tikva,
 Israel
- ⁸ Department of Medical Genetics, Eskisehir City Hospital, 71 Evler Mahallesi, Çavdarlar Sk.,
- 16 26080, Odunpazarı/Eskişehir, Turkey
- ⁹ Department of Medical Education, Graduate School of Medicine, Chiba University, Chiba, Japan
- ¹⁰ Department of Advanced Biomedical Sciences, University of Naples "Federico II," Naples, Italy
- ¹¹ Department of Pediatrics, Diabetes Research Institute IRCCS San Raffaele Hospital, Milan, Italy
- 20 ¹² Neuroradiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
- 21 ¹³ Department of Neurology, Royal Perth Hospital, Perth, WA, Australia
- ¹⁴ Department of Human Genetics, McGill University, Montreal, QC, Canada
- 23 ¹⁵ Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO,
- 24 USA
- ¹⁶ Department of Neurology, Pitié-Salpêtrière University Hospital, Paris, France
- ¹⁷ Department of Diagnostic Radiology, McGill University, Montreal, QC, Canada
- 27
- 28 * Correspondence:
- 29 Roberta La Piana
- 30 roberta.lapiana@mcgill.ca

31 Abstract

32 Background and Objectives

33

Background and Objectives

34 Wolfram syndrome (WFS) is a genetic disorder mainly caused by pathogenic variants in the *WFS1*

35 gene. It is characterized clinically by optic atrophy (OA), diabetes mellitus (DM), sensorineural

hearing loss (SNHL), diabetes insipidus (DI), and variable neurological/psychiatric symptoms. WFS twpicelly manifests before and 20 and progresses into adulthood. Classical resurrential scientific terms of the second se

typically manifests before age 20 and progresses into adulthood. Classical neuroradiological features
 include cerebellar and/or brainstem atrophy as well as white matter abnormalities ranging from small,

39 ovoid lesions to diffuse, symmetrical changes along the visual pathway. Following the identification

40 of multifocal, progressive white matter abnormalities that prompted the consideration of multiple

41 sclerosis (MS) in two molecularly confirmed WFS subjects, we sought to verify whether MS-like

- 42 lesions constitute a novel WFS-associated MRI pattern.
- 43
- 44 <u>Methods</u>
- 45

46 We conducted an international multicenter retrospective study of the clinical, genetic, and 47 rediclogical data from 17 unrelated WES subjects

- 47 radiological data from 17 unrelated WFS subjects.48
- 49 <u>Results</u>
- 50

51 Seven subjects (7/17; 41%) showed at least one focal white matter lesion evocative of MS. Among 52 these seven, three fulfilled the McDonald radiological criteria of dissemination in space and time, 53 suggesting an inflammatory demyelinating process. All subjects reviewed in the study had at least

- 54 one of the classical WFS MRI features.
- 55

56 <u>Conclusions</u> 57

58 Our report expands the WFS spectrum of white matter involvement to include progressive, seemingly

59 inflammatory demyelinating lesions. While we cannot exclude the possibility of a WFS-MS dual

60 diagnosis in some cases, the role of *WFS1* in myelination suggests a selective white matter

61 vulnerability in WFS. Our findings suggest that follow up MRI should be recommended to adult

62 subjects with WFS. Further identification and longitudinal study of adult WFS subjects is required to

63 confirm whether a WFS molecular diagnosis confers susceptibility to the development of MS.

64 1 Introduction

65 Wolfram syndrome (WFS) is a rare genetic spectrum disorder characterized clinically as any

66 combination of optic atrophy (OA), diabetes mellitus (DM), diabetes insipidus (DI), and

67 sensorineural hearing loss (SNHL), accompanied by other neurological and/or psychiatric features¹⁻⁴.

68 These latter features, seen in over 50% of cases, are usually progressive and include cerebellar ataxia,

69 brainstem dysfunction, epilepsy, and cognitive disability³. Biallelic or monoallelic pathogenic

- variants in *WFS1* cause WFS, putatively through loss-of-function mechanisms that undermine
- endoplasmic reticulum (ER)-mitochondria dynamics and trigger unfolded protein response (UPR)-
- 72 mediated cell death $^{5-11}$.

From a neuroimaging perspective, although different CNS structures are involved, the most 73 74 common imaging findings reported in WFS are cerebellar atrophy, brainstem atrophy, and signal 75 changes along the visual pathway, posterior pituitary gland, pontine fibers, and cerebral white 76 matter^{12–15}. In particular, the patterns of white matter abnormalities range from small multifocal, ovoid-shaped T2-hyperintense lesions to symmetrical, diffuse involvement¹²⁻¹⁷. MRI findings in 77 78 WFS can appear as early as the first decade, even when neurological symptoms are absent or barely 79 noticeable, and they progress over time^{3,9,10,12,18}. Interestingly, they seem to be coupled to more 80 profound abnormalities that can be detected through advanced imaging techniques. These include microstructural alterations of the white matter in early myelinating structures (i.e., brainstem, 81 82 posterior periventricular white matter), fueling the hypothesis that hypomyelination may play a role

83 and precede adult stage neurodegeneration in $WFS^{9,10,14}$.

84 In agreement with conventional and advanced neuroimaging findings that indicate white matter involvement in WFS, molecular studies strongly suggest that WFS1 could play a vital role in 85 establishing and maintaining white matter integrity^{17,19–24}. To this end, it has been speculated that the 86 87 pathophysiology of CNS features in WFS could at least in part overlap that of more common demyelinating diseases, such as multiple sclerosis (MS)¹⁴. In line with these speculations, and after 88 89 identifying two unrelated, genetically confirmed WFS subjects through the White Matter Rounds 90 Network²⁵, in which multifocal, progressive, and contrast-enhancing white matter abnormalities led to the consideration of MS, we aimed to assess the prevalence of likely inflammatory white matter 91 92 lesions and MS diagnosis in subjects with WFS.

- 93 2 Materials and methods
- 94 2.1 Participants

We conducted an international, multicenter retrospective review of the clinical,
 neuroradiological, and molecular data of subjects with the following inclusion criteria:

97

98 99

- 1) Clinical diagnosis of WFS, defined as the presence of:
 - a. At least two of the four classical WFS features (OA, DM, DI, and SNHL).
 - b. At least <u>one</u> neurological or psychiatric symptom in addition to SNHL and OA.

100Patients with Wolfram-like syndrome (at least <u>one</u> classical feature plus one101neurological/psychiatric symptom aside from SNHL and OA) were included if they had a102positive WFS family history.

- 103 2) If above criterion not met, genetic diagnosis molecularly confirmed by detection of
 104 pathogenic or likely pathogenic variants in the *WFS1* gene, classified according to ACMG
 105 guidelines²⁶, through an accredited clinical diagnostic laboratory.
- Available brain MRI with axial and sagittal T2-weighted and T2-FLAIR images at minimum.
 Any additional brain MR sequences or spinal cord images for subjects meeting this minimum
- 108 requirement were also reviewed.

To achieve this, we contacted the corresponding authors of previously published WFS case reports and series (150 subjects). Ten authors responded and agreed to participate. We therefore included 17 subjects from seven countries: Canada (1), France (1), Israel (2), USA (8), Italy (3), Turkey (1), and Japan (1).

113 2.2. Data Analysis

For each included subject, we collected the following demographic and clinical data: sex, family history, age at onset (defined as the age at which at least one WFS classical feature or neurological/psychiatric deficit appeared), age at latest examination, and presence of ataxia/cerebellar signs, spasticity, abnormal reflexes, other movement disorders, cranial nerve dysfunction, vertigo, tinnitus, migraine, neuropathy, seizures, psychiatric disorders, cognitive deficits, sphincter dysfunction, and extra-neurological signs.

- 120 The MRI images were reviewed independently by two teams of raters:
- 121 a) JS and RLP, with >15 years of experience in white matter disorders.
- b) A neuroradiologist from each participating institution (SC/GF-CB for cases from Italy, AWY-YG for cases from Israel, AK for the case from Turkey, and SI for the case from Japan) or a neuroradiologist from outside the study (EM, with >20 years of experience, for all cases from Canada, USA, and France).
- When available, for 10 subjects (10/17; 58.8% of the entire cohort), each MRI scan was reevaluated four months later, blind to the initial MRI interpretation, with a focus on the multifocal white matter abnormalities documented in each subject. The raters remained blind to the clinical data during each review session to further mitigate lesion classification bias. Disagreements between raters were resolved by consensus.

131 We performed a qualitative analysis of all available MRI images to assess the presence and 132 characteristics of the white matter abnormalities. The following criteria were analyzed: location 133 (periventricular, subcortical, juxtacortical), lobar involvement (frontal, temporal, parietal, occipital, 134 cerebellar), pattern of involvement (multifocal, confluent, diffuse), symmetry, and enhancement 135 following gadolinium injection. In our study, a lesion was defined as a focal area of T2-hyperintense 136 signal in the CNS white matter. Juxtacortical lesions were defined as lesions in direct contact with 137 the cortical ribbon. Periventricular lesions included all lesions abutting any portion of lateral 138 ventricles as well as intracallosal lesions and linear plate-like bandings. Subcortical lesions were 139 defined as supratentorial non-juxtacortical, non-periventricular white matter lesions. MS-like lesions 140 were defined as round/ovoid areas of T2-hyperintense signal at least 3mm in long axis²⁷⁻²⁹. MR 141 images were also evaluated for cerebral, brainstem, and cerebellar (hemispheric and vermian) 142 atrophy and when possible, depending on the available sequences, other associated features such as 143 gray matter involvement, microvascular changes, and calcifications. When spinal cord MRI was 144 available, we evaluated it for the presence of signal abnormalities and atrophy. Given the nature of

145 this retrospective review, there were intrinsic limitations in the analysis, as MRI examinations

slightly differed in imaging quality and techniques.

147 2.3 Standard Protocol Approvals, Registrations, and Patient Consent

Access to patient medical histories and results of diagnostic investigations for collaborative

retrospective study was granted by the review boards of each participating institution, in conformity to respective anonymization procedures.

151 **3 Results**

152 **Table 1** contains the clinical, genetic, and radiological data from the 17 included subjects.

153 3.1 Clinical findings

154 Demographic and clinical data were available for 16/17 subjects (94.1%); for one subject the 155 only information was the sex, the age at last examination, and the confirmed molecular diagnosis. 156 The cohort included nine female subjects (52.9%). Median age at onset of WFS was 15.5 years 157 (range = 3-35 years). Regarding classical WFS features, nearly all exhibited OA (n = 15/16; 94%) 158 except for one subject (#2), who had diminished visual acuity with a normal fundoscopic 159 examination. Thirteen had DM (n = 13/16; 81%), nine had SNHL (n = 9/16; 57%), and seven had DI 160 (n = 7/16; 44%). In all subjects except subject #11, for whom the first sign was non-syndromic 161 epilepsy, the first sign(s) included one or multiple classical WFS features (n = 15/16; 94%), most 162 commonly DM. Two subjects, #3 and #15, developed cataract, an uncommon, yet known WFS 163 feature, at some point in the clinical course (n = 2/16; 13%).

164 Neurological and/or psychiatric symptoms, aside from OA and SNHL, manifesting several 165 years post-onset (median = 6 years; range = 3-42 years), were documented in all subjects (n = 16/16; 166 100%), consistent with the neurodegenerative character of WFS.

167 Two subjects, #2 and #3 (n = 2/16; 13%), presented acute focal deficits in the third/fourth 168 decade that may be related to active demyelination as shown on MRI. These included hyperreflexia 169 and fine motor impairment (subject #2) and truncal ataxia, appendicular ataxia, and dysarthria 170 (subject #3).

171 3.2. Genetic findings

Pathogenic or likely pathogenic variants in *WFS1* (mono- or biallelic) were documented in all subjects for whom genetic testing had been performed (n = 16 tested/17 total; 94%). Subject #15 was diagnosed with Wolfram-like syndrome after detection of a monoallelic pathogenic *WFS1* variant through whole genome sequencing, which was performed because of unusual MRI features.

Family history was noteworthy for symptoms along the WFS spectrum in most subjects for whom this information was available (n = 10/15; 66%). The family history was positive for WFS in three cases (n = 3/15; 20%), cataract in three (n = 3/15; 20%), and cardiac anomalies/syndromes in two (n = 2/15; 13%), which have also been reported in WFS.

180 3.3. Neuroimaging findings

181 The mean age at the latest MRI available for review was 29 years old (range = 14-60 years). 182 All subjects demonstrated at least one neuroradiological feature typical of WFS (**Figure 1**)¹²⁻¹⁵. For 183 11 subjects (n = 11/17; 65%), two timepoints were available for assessment (mean follow-up MRI 184 duration = 5.3 years).

185 Classical WFS-associated features

186 Involvement of the posterior periventricular white matter and/or optic radiations was the most 187 common finding (n = 15/17; 88%), followed by punctate subcortical white matter changes (n = 9/17; 188 53%), pontine signal changes (n = 7/17; 41%), brainstem atrophy (n = 6/17; 35%), cerebellar atrophy 189 (n = 5/17; 29%), diffuse/confluent involvement of the centrum semiovale and/or peritrigonal white 190 matter (n = 4/17; 24%), and absent/diminished T1-weighted posterior pituitary bright spot (n = 1/17; 191 6%).

192 Enlarged perivascular spaces (n = 3/17; 18%), corpus callosum abnormalities (n = 3/17; 193 18%), midbrain signal changes (n = 2/17; 12%), and abnormal occipital lobe gyrification with or 194 without posterior horn ventricular enlargement (n = 2/17; 12%) were additionally observed.

195 <u>MS-like white matter abnormalities</u>

We detected T2-hyperintense white matter foci that were MS plaque-like^{27–29} in seven subjects 196 197 (n = 7/17; 41%) (Figures 2 and 3). In four of these subjects (n = 4/17; 24%), the McDonald 198 radiological criteria of dissemination in space and time were either fully (n = 3) or partially (n = 1)199 fulfilled, inciting consideration of a WFS-MS double diagnosis (Figure 2)²⁷. Some lesions in three of 200 these four subjects showed gadolinium enhancement on T1-weighted imaging (Figure 2A), further 201 supporting the existence of an underlying inflammatory process. Positive oligoclonal band status 202 strongly supported a secondary diagnosis of MS in the only two subjects for whom lumbar puncture 203 was performed (#2 and #3). In both cases, a secondary diagnosis of MS was communicated, and MS 204 treatment with teriflunomide was initiated in subject #3. Follow-up MRI after teriflunomide initiation 205 documented stabilization of the multifocal white matter lesion load with worsening of pre-existing 206 cerebellar atrophy and diffuse bilateral subcortical white matter involvement (Figure 2G-I). The 207 observed locations and characteristics of MS-like focal lesions are summarized in Table 2.

During blind re-analysis four months after the first image review, it was agreed that three subjects (#7, #8, and #13) had focal lesions not strictly belonging to either category (WFS- or MSlike/demyelinating) (Figure 3D; see Table 1 for initial lesion categorization in each subject). The areas of suspicion were in the subcortical white matter and included two or more small, round, yet non-ovoid T2-hyperintense lesions close to one another. The lesions did not correspond to enlarged perivascular spaces.

214 4 Discussion

In this study, we report WFS subjects presenting with neuroradiological and, in some cases, clinical profiles compatible with a diagnosis of MS. The identification of four subjects with seemingly inflammatory white matter lesions that fully or partially fulfilled the McDonald criteria for MS diagnosis raises the possibility that a WFS molecular diagnosis may predispose to the development of neuroinflammatory white matter disorders such as MS. In fact, the worldwide prevalence estimates of MS (~1:2800)³⁰ and WFS (~1:500 000)^{31,32} argue against coincidental occurrence of WFS and focal demyelinating events but rather suggest pathophysiological overlap

between MS and WFS.

Our series focuses on MR imaging of adult subjects with WFS, who have been far less studied by imaging than pediatric subjects. Our findings suggest that secondary neuroinflammation, even when it does not satisfy the full criteria for MS, might contribute to gradual neurological and/or psychiatric decline in WFS⁹. Therefore, we recommend follow-up of WFS patients beyond adolescence to monitor the onset of inflammatory demyelinating lesions.

Importantly, multifocal white matter lesions have been previously described in WFS, albeit not with the usual features of MS plaques. Thus, the risk for individuals with Wolfram-like syndrome (i.e., partial WFS) to receive an incorrect primary diagnosis of MS is not negligible given the variability in neurological progression seen across subjects. We recommend that genetic testing for WFS be performed when a subject presents with multifocal white matter lesions – either seemingly

233 inflammatory or not – and at least one of the classic diagnostic features of WFS.

234 In line with the hypothesis that some subjects in our study may be concomitantly suffering 235 from WFS and MS, subject #3 responded to teriflunomide (Figure 2G-I). This was the only subject 236 in our series who had started disease-modifying therapy for MS. While there is a possibility that the 237 treatment had no impact on the natural course of WFS in this subject, it is plausible that underlying 238 degenerative processes may have been exacerbated while inflammation was being suppressed. Even 239 though the exact mechanisms contributing to this subject's outcome remain undefined, simultaneous 240 wolframin/WFS1 deficiency and teriflunomide treatment might have imposed a significant 241 mitochondrial stressor. Indeed, Wolframin/WFS1 plays an indirect, yet essential role in multiple 242 facets of mitochondrial quality control putatively through modulation of Ca²⁺ homeostasis, while the 243 mechanism of action of teriflunomide is the inhibition of dihydroorotate dehydrogenase, whose 244 activity is intrinsically linked to the mitochondrial respiratory chain^{19,33}. Thus, the classic WFS-245 associated neuroradiological features in this subject might have progressed, at least in part, because 246 of a compounded mitochondrial insult, although dedicated studies are needed to validate this 247 speculation.

248 Existing molecular evidence insists that unchecked tissue-specific and systemic inflammatory processes are significant drivers of WFS pathogenesis^{34–38}. For example, in the context of DM, 249 250 several works suggest that loss of wolframin protein (Wfs1) in murine pancreatic β -cells causes ER 251 stress-mediated NLRP3 inflammasome activation and subsequent apoptosis by means of upregulated expression of pro-inflammatory cytokines, namely IL-1β^{35,37,38}. β-cells lacking wolframin in turn 252 253 show disproportionate increases in ER stress and pro-inflammatory mediator expression in response 254 to applied cytokines and hyperglycemia, forming a positive feedback cycle that likely exacerbates 255 DM in WFS³⁵. In the context of OA, early stage optic nerve demyelination in *Wfs1*-KO mice is 256 marked by ER stress-mediated STAT3 activation and an overall pro-neuroinflammatory, anti-257 survival transcriptomic shift in local glial populations³⁴. This shift is associated with a downregulation of glial MCT1 that hampers neuron-bound lactate shuttling capacity, instigating 258 259 retinal ganglion cell degeneration over time³⁴. Critically, lower expression of MCT1 was additionally 260 detected in the cortex and striatum of the mice, indicating that these neuroinflammatory 261 transcriptomic shifts may tile the entire brain³⁴. Furthermore, in a recent WFS case report, patient-262 derived peripheral blood mononuclear cells (PBMCs), which were anomalously wolframin-deficient, 263 showed constitutively high, UPR-independent expression of pro-inflammatory cytokines that 264 correlated with hypercytokinemia (TNF- α , IL-1 β , and IL-6) and a positively skewed T_h17/T_{reg} ratio—signs of systemic inflammation³⁷. A chronic, systemic inflammatory state characterized by 265 266 hypercytokinemia was also corroborated in a WFS mouse model³⁵. Such findings are particularly 267 intriguing given the large body of evidence implicating T_h17 cells in MS pathogenesis, importantly during the acute phase of disease³⁹. Taken together, these studies implicate wolframin in the 268

269 regulation of parallel inflammatory signaling cascades that are perhaps simultaneously brewing in a

270 WFS individual. Our result of focal enhancement post-contrast being observed in all radiological

MS-mimicking subjects for whom this investigation was performed (subjects #2, #3, and #4), when

interpreted alongside a potential chronic T_h17 -driven systemic inflammatory process and generalized neuroinflammatory state, begs the question of whether MS-overlapping pathology could arise in

274 WFS.

275 In our review, some lesions were interpreted as neither MS- nor WFS-like. In the 276 corresponding subjects, gadolinium administration was not performed, so we do not know whether 277 these lesions could be inflammatory. This observation further supports the idea of a continuum 278 between white matter involvement classically seen in WFS and in neuroinflammation. The 279 identification of signs currently considered specific for MS, namely the central vein sign (CVS), could help in further classifying white matter lesions in WFS⁴⁰. CVS could not be validated in our 280 281 subjects due to a lack of susceptibility-weighted imaging sequences, no reconstructible planes, and 282 probably insufficient field strength. Higher field imaging (7T MRI) could prove useful in not only 283 detecting CVS, as demonstrated by a recent study evaluating the diagnostic performance of 3T vs. 7T 284 MRI in MS⁴¹, but also in better depicting the signal characteristics of white matter abnormalities in

285 WFS subjects, which may help differentiate WFS from MS by imaging.

A recent prospective study has supported the addition of the optic nerve as a fifth CNS location within the McDonald radiological criterion of dissemination in space⁴². Since dedicated optic nerve MRI was only performed in one subject from our cohort (who did not have a confirmed molecular diagnosis), and as mentioned, adult WFS subjects have been far less studied than pediatric subjects, the prevalence of optic nerve lesions in the adult WFS population remains unknown. Consequently, the proportion of WFS patients who will satisfy MS diagnostic criteria because of the proposed modification to the criteria cannot be estimated at this time.

Our study has several limitations, namely its retrospective nature (which precluded the use of advanced imaging techniques), the obstacles related to the identification and inclusion of adult WFS patients, and the lack of follow-up MRI in a considerable number of subjects. Future prospective imaging studies can help clarify the nature of white matter involvement in adult patients with WFS.

In conclusion, our report expands the WFS spectrum of white matter involvement to include late-onset progressive, seemingly inflammatory demyelinating lesions that, in the context of supportive clinical and laboratory findings, can prompt consideration of MS. We emphasize the need for continuous radiological follow-up of WFS patients into early and middle adulthood, and the utility of international collaboration in this regard, for better characterization of age- and/or immunerelated MRI patterns. In the future, these results may lead to the inclusion of WFS to the growing list of single-gene disorders with the potential to mimic or confer susceptibility to MS^{43,44}.

304 5 Conflict of Interest

305 The authors have no conflicts of interest to declare.

306 6 Author Contributions

JS: manuscript writing and project coordination (contacting WFS authors, collection, compilation,
 and analysis of data, via conference call or email correspondence, from all authors who accepted to
 collaborate). EM: external neuroradiologist invited for MRI review. HML & TH: data collection

310 from WFS cohort followed at Washington University, USA (eight subjects). AWY & YG: data

- 311 collection from two WFS subjects followed at Tel Aviv University, Israel. AK: data collection from
- 312 one Wolfram-like syndrome subject followed at Eskisehir City Hospital, Turkey. SI: data collection
- from one WFS subject followed at Chiba University, Japan. SC: data collection from one WFS
- 314 subject seen at University of Naples "Federico II," Italy. GF & CB: data collection from two
- subjects, derived from a larger cohort of 16 pre-screened WFS subjects (of which six were adults)
- seen at San Raffaele Hospital, Italy. AB: analysis of compiled data. CA, GR, & RLP: data collection
- 317 from one WFS subject followed at McGill University, Canada. YN: data collection from one WFS 318 subject followed at Pitié-Salpêtrière University Hospital, France. RLP: conceptualization of the
- study, analysis of compiled data, funding acquisition, and review and editing of the manuscript.

320 7 Funding

321 JS has received scholarships from the Canadian Institutes of Health Research (CIHR) and the Fonds de

322 Recherche du Québec en Santé (FRQS). RLP has received a Research Scholar Junior 1 award from the

323 FROS, research funds from the Canadian Radiological Foundation, the Spastic Paraplegia Foundation, and

324 received funds for further data on this project from Hoffman-La Roche Limited.

325 8 Acknowledgment

This work would not have been possible without our international collaborators, who are members of the <u>White Matter Rounds Network</u>:

328

329 "Adult genetic leukoencephalopathies are rare neurological disorders that present unique diagnostic

330 challenges due to their clinical and radiological overlap with more common white matter diseases, notably

331 multiple sclerosis (MS). In this context, a strong collaborative multidisciplinary network is beneficial for

332 shortening the diagnostic odyssey of these patients and preventing misdiagnosis. The White Matter Rounds

333 *(WM Rounds) are multidisciplinary international online meetings attended by more than 30 physicians*

and scientists from 15 participating sites that gather every month to discuss patients with atypical white

335 *matter disorders.* [...] *The WM Rounds Network demonstrate*[s] *the value of collaborative*

336 multidisciplinary international case discussion meetings in differentiating and preventing misdiagnoses

- 337 between genetic white matter diseases and atypical MS."
- Huang YT, et al. The White Matter Rounds experience: The importance of a multidisciplinary network to accelerate the diagnostic process for adult patients with rare white matter disorders. *Front. Neurol.* (2022) 13:928493. doi: 10.3389/fneur.2022.928493

341 9 References

- Barrett T, Bundey SE, Macleod AF. (DIDMOAD) syndrome UK nationwide study of
 Wolfram. *Lancet*. 1995;346:1458-1463.
- Shannon P, Becker L, Deck J. Evidence of widespread axonal pathology in Wolfram
 syndrome. *Acta Neuropathol.* 1999;98(3):304-308. doi:10.1007/s004010051084
- 346 3. Chaussenot A, Bannwarth S, Rouzier C, et al. Neurologic features and genotype-phenotype
 347 correlation in Wolfram syndrome. *Ann Neurol.* 2011;69(3):501-508. doi:10.1002/ana.22160
- Urano F. Wolfram Syndrome: Diagnosis, Management, and Treatment. *Curr Diab Rep.* 2016;16(1):1-8. doi:10.1007/s11892-015-0702-6
- Inoue H, Tanizawa Y, Wasson J, et al. A gene encoding a transmembrane protein is mutated in
 patients with diabetes mellitus and optic atrophy (Wolfram syndrome). *Nat Genet*.
 1998;20(2):143-148. doi:10.1038/2441
- Amr S, Heisey C, Zhang M, et al. A homozygous mutation in a novel zinc-finger protein,
 ERIS, is responsible for Wolfram syndrome 2. *Am J Hum Genet*. 2007;81(4):673-683.
 doi:10.1086/520961
- Bai X, Lv H, Zhang F, et al. Identification of a novel missense mutation in the WFS1 gene as a
 cause of autosomal dominant nonsyndromic sensorineural hearing loss in all-frequencies. *Am J Med Genet Part A*. 2014;164(12):3052-3060. doi:10.1002/ajmg.a.36760
- Rouzier C, Moore D, Delorme C, et al. A novel CISD2 mutation associated with a classical
 Wolfram syndrome phenotype alters Ca2+ homeostasis and ER-mitochondria interactions.
 Hum Mol Genet. 2017;26(9):1599-1611. doi:10.1093/hmg/ddx060
- 362 9. Samara A, Rahn R, Neyman O, et al. Developmental hypomyelination in Wolfram syndrome:
 363 New insights from neuroimaging and gene expression analyses. *Orphanet J Rare Dis.*364 2019;14(1):1-14. doi:10.1186/s13023-019-1260-9
- Loncke J, Vervliet T, Parys JB, Kaasik A, Bultynck G. Uniting the divergent Wolfram
 syndrome–linked proteins WFS1 and CISD2 as modulators of Ca2+ signaling. *Sci Signal*.
 2021;14(702). doi:10.1126/scisignal.abc6165
- I1. Zmyslowska A, Kuljanin M, Malachowska B, et al. Multiomic analysis on human cell model
 of wolfram syndrome reveals changes in mitochondrial morphology and function. *Cell Commun Signal*. 2021;19(1):1-14. doi:10.1186/s12964-021-00791-2
- Hershey T, Lugar HM, Shimony JS, et al. Early brain vulnerability in Wolfram syndrome.
 PLoS One. 2012;7(7). doi:10.1371/journal.pone.0040604
- Lugar HM, Koller JM, Rutlin J, et al. Neuroimaging evidence of deficient axon myelination in
 Wolfram syndrome. *Sci Rep.* 2016;6(February):1-13. doi:10.1038/srep21167
- Lugar HM, Koller JM, Rutlin J, et al. Evidence for altered neurodevelopment and
 neurodegeneration in Wolfram syndrome using longitudinal morphometry. *Sci Rep.*

- 377 2019;9(1):1-11. doi:10.1038/s41598-019-42447-9
- Samara A, Lugar HM, Hershey T, Shimony JS. Longitudinal assessment of neuroradiologic
 features in wolfram syndrome. *Am J Neuroradiol*. 2020;41(12):2364-2369.
 doi:10.3174/ajnr.A6831
- Labauge P, Renard D, Chaussenot A, Paquis-Flucklinger V. Wolfram syndrome associated
 with leukoencephalopathy. *J Neurol Neurosurg Psychiatry*. 2010;81(8):928.
 doi:10.1136/jnnp.2009.185579
- Kocaaga A, Yimenicioglu S, Bayav M. A p.Val412Serfs pathogenic variant associated with
 Wolfram-like syndrome and leukodystrophy. *Egypt J Neurol Psychiatry Neurosurg*.
 2023;59(1):4-9. doi:10.1186/s41983-023-00608-8
- Wilf-Yarkoni A, Shor O, Fellner A, et al. Mild Phenotype of Wolfram Syndrome Associated
 With a Common Pathogenic Variant Is Predicted by a Structural Model of Wolframin. *Neurol Genet*. 2021;7(2):e578. doi:10.1212/nxg.00000000000578
- Cagalinec M, Liiv M, Hodurova Z, et al. Role of Mitochondrial Dynamics in Neuronal Development: Mechanism for Wolfram Syndrome. *PLoS Biol.* 2016;14(7):1-28. doi:10.1371/journal.pbio.1002511
- Plaas M, Seppa K, Reimets R, et al. Wfs1-deficient rats develop primary symptoms of
 Wolfram syndrome: Insulin-dependent diabetes, optic nerve atrophy and medullary
 degeneration. *Sci Rep.* 2017;7(1):1-16. doi:10.1038/s41598-017-09392-x
- 396 21. Sakakibara Y, Sekiya M, Fujisaki N, Quan X, Iijima KM. Knockdown of wfs1, a fly homolog
 397 of Wolfram syndrome 1, in the nervous system increases susceptibility to age- and stress398 induced neuronal dysfunction and degeneration in Drosophila. *PLoS Genet*. 2018;14(1):1-25.
 399 doi:10.1371/journal.pgen.1007196
- Chen YF, Kao CH, Chen YT, et al. Cisd2 deficiency drives premature aging and causes
 mitochondria-mediated defects in mice. *Genes Dev.* 2009;23(10):1183-1194.
 doi:10.1101/gad.1779509
- 403 23. Pourtoy-Brasselet S, Sciauvaud A, Boza-Moran MG, et al. Human iPSC-derived neurons
 404 reveal early developmental alteration of neurite outgrowth in the late-occurring
 405 neurodegenerative Wolfram syndrome. *Am J Hum Genet*. 2021;108(11):2171-2185.
 406 doi:10.1016/j.ajhg.2021.10.001
- 407 24. Kitamura RA, Maxwell KG, Ye W, et al. Multidimensional analysis and therapeutic
 408 development using patient iPSC-derived disease models of Wolfram syndrome. *JCI Insight*.
 409 2022;7(18). doi:10.1172/jci.insight.156549
- 410 25. Huang YT, Giacomini PS, Massie R, et al. The White Matter Rounds experience: The
 411 importance of a multidisciplinary network to accelerate the diagnostic process for adult
 412 patients with rare white matter disorders. *Front Neurol.* 2022;13.
 413 doi:10.3389/fneur.2022.928493
- 414 26. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence

415 variants: a joint consensus recommendation of the American College of Medical Genetics and
416 Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17(5):405-424.
417 doi:10.1038/gim.2015.30

- 418 27. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions
 419 of the McDonald criteria. *Lancet Neurol*. 2018;17(2):162-173. doi:10.1016/S1474420 4422(17)30470-2
- 421 28. Rovira À, Wattjes MP, Tintoré M, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic
 423 process. *Nat Rev Neurol.* 2015;11(8):471-482. doi:10.1038/nrneurol.2015.106
- Filippi M, Preziosa P, Banwell BL, et al. Assessment of lesions on magnetic resonance
 imaging in multiple sclerosis: practical guidelines. *Brain*. 2019;142(7):1858-1875.
 doi:10.1093/brain/awz144
- Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide:
 Insights from the Atlas of MS, third edition. *Mult Scler*. 2020;26(14):1816-1821.
 doi:10.1177/1352458520970841
- 430 31. Rigoli L, Caruso V, Salzano G, Lombardo F. Wolfram Syndrome 1: From Genetics to
 431 Therapy. *Int J Environ Res Public Health*. 2022;19(6). doi:10.3390/ijerph19063225
- 432 32. Rigoli L, Bramanti P, Di Bella C, De Luca F. Genetic and clinical aspects of Wolfram
 433 syndrome 1, a severe neurodegenerative disease. *Pediatr Res.* 2018;83(5):921-929.
 434 doi:10.1038/pr.2018.17
- 435 33. Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. *Am J Med.*436 2020;133(12):1380-1390.e2. doi:10.1016/j.amjmed.2020.05.049
- 437 34. Rossi G, Ordazzo G, Vanni NN, et al. MCT1-dependent energetic failure and
 438 neuroinflammation underlie optic nerve degeneration in Wolfram syndrome mice. *Elife*.
 439 2023;12:1-25. doi:10.7554/eLife.81779
- 440 35. Morikawa S, Blacher L, Onwumere C, Urano F. Loss of Function of WFS1 Causes ER Stress441 Mediated Inflammation in Pancreatic Beta-Cells. *Front Endocrinol (Lausanne)*.
 442 2022;13(March):1-12. doi:10.3389/fendo.2022.849204
- 443 36. Fonseca SG, Ishigaki S, Oslowski CM, et al. Wolfram syndrome 1 gene negatively regulates
 444 ER stress signaling in rodent and human cells. *J Clin Invest*. 2010;120(3):744-755.
 445 doi:10.1172/JCI39678
- 446 37. Panfili E, Mondanelli G, Orabona C, et al. Novel mutations in the WFS1 gene are associated
 447 with Wolfram syndrome and systemic inflammation. *Hum Mol Genet*. 2021;30(3-4):265-276.
 448 doi:10.1093/hmg/ddab040
- 38. Oslowski CM, Hara T, O'Sullivan-Murphy B, et al. Thioredoxin-interacting protein mediates
 ER stress-induced β cell death through initiation of the inflammasome. *Cell Metab*.
 2012;16(2):265-273. doi:10.1016/j.cmet.2012.07.005

- 452 39. Moser T, Akgün K, Proschmann U, Sellner J, Ziemssen T. The role of TH17 cells in multiple
 453 sclerosis: Therapeutic implications. *Autoimmun Rev.* 2020;19(10):102647.
 454 doi:10.1016/j.autrev.2020.102647
- 40. Maggi P, Absinta M, Grammatico M, et al. Central vein sign differentiates Multiple Sclerosis
 456 from central nervous system inflammatory vasculopathies. *Ann Neurol.* 2018;83(2):283-294.
 457 doi:10.1002/ana.25146
- 458 41. Okromelidze L, Patel V, Singh RB, et al. Central Vein Sign in Multiple Sclerosis: A
 459 Comparison Study of the Diagnostic Performance of 3T versus 7T MRI. *Am J Neuroradiol*.
 460 2024;45(1):76-81. doi:10.3174/ajnr.A8083
- 461 42. Vidal-Jordana A, Rovira A, Calderon W, et al. Adding the Optic Nerve in Multiple Sclerosis
 462 Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study. *Neurology*. 2024;102(1).
 463 doi:10.1212/WNL.00000000207805
- 464 43. Weisfeld-Adams JD, Sand IBK, Honce JM, Lublin FD. Differential diagnosis of Mendelian
 465 and mitochondrial disorders in patients with suspected multiple sclerosis. *Brain*.
 466 2015;138(3):517-539. doi:10.1093/brain/awu397
- 467 44. Ayrignac X, Carra-Dallière C, Marelli C, Taïeb G, Labauge P. Adult-Onset Genetic Central
 468 Nervous System Disorders Masquerading as Acquired Neuroinflammatory Disorders: A
 469 Review. JAMA Neurol. 2022;79(10):1069-1078. doi:10.1001/jamaneurol.2022.2141
- 470 45. De Michele G, Maione L, Cocozza S, et al. Ataxia and Hypogonadism: a Review of the
 471 Associated Genes and Syndromes. *Cerebellum*. 2024;23(2):688-701. doi:10.1007/s12311-023472 01549-x
- 473 46. Ito S, Sakakibara R, Hattori T. Wolfram syndrome presenting marked brain MR imaging
 474 abnormalities with few neurologic abnormalities. *Am J Neuroradiol.* 2007;28(2):305-306.

475

476 **10** Tables and Figures

Subject ^{ref}	Origin	Age at onset/last exam (decade)	Zygosity	WFS1 variants (NM_006005.3)	Classic WFS symptoms	Neurological symptoms	Age at last MRI (decade)	Classical WFS MRI features	MS-like white matter foci	Dissemination in space and/or time	Gadolinium enhancement	Additional investigations or interventions	Full McDonald criteria (clinical + radiological)
1	Canada	30s/40s	Het	c.2389G>A, p.D797N	SNHL, OA	Hypor, M, PN	40s	Pit, PVp, Pun	Sub, PV/Cal, JxU	Yes, space + time**	N/P	N/P	Partially fulfilled
2	France	10s/30s	C Het	c.1112G>A, p.W371* c.1511C>G, p.P504R	DM, Vision loss	Hyperr, A, B	20s	D	Sub, PV/Cal, SC	Yes, space + time**	Yes (Cal; Sub)	LP: inflammatory profile w/ OCBs	Fulfilled
3	Israel	10s/30s	Hom	c.1230_1233delCTCT, p.V412Sfs	SNHL, OA, C	A, Hypor, S	30s	CA, PVp, D	Sub, JxU, PV, Cer, SC	Yes, space + time**	Yes (Sub – parietal)	LP: elevated WBCs w/ OCBs; MS-like foci stabilized upon teriflunomide use, while non- focal abnormalities progressed	Fulfilled
4 ¹⁸	Israel	10s/60s	Hom	c.1672C>T, p.R558C	DM, OA	A, CD, B	60s	D, PVp	Sub	Yes, time only	Yes (Sub – occipital)	N/P	Partially fulfilled
5 ⁴⁵	Italy	Unknown/50s	N/A	N/A	N/A	N/A	50s	CA, BA, PVp	-	-	N/P	N/P	-
6 ⁴⁶	Japan	0s/30s	N/P	N/P	DM, SNHL, OA	DCo	30s	CA, BA, Pit, D, PVp	-	-	N/P	N/P	-
7 ¹⁴	USA	10s/20s	C Het	c.817G>T, p.E273* c.1839G>A, p.W613*	DM, DI, SNHL, OA	A, Mo, S, Psy, CD, B	10s	Po, PVp, Pun†	PV	-	N/P	N/P	-
8 ¹⁴	USA	10s/20s	C Het	c.605A>G, p.E202G c.631G>A, p.D211N	DM, OA	А	20s	CA, PVp (unilateral), Pun	Sub†	-	N/P	N/P	-
9 ¹⁴	USA	10s/20s	C Het	c.376G>A, p.A126T c.1838G>A, p.W613*	DM, DI, OA	A, Psy, B	20s	Po, PVp, Pun	-	-	N/P	N/P	-
10 ¹⁴	USA	20s/30s	C Het	c.1240_1242del, p.P414del c.1698_1703del, p.L567_P568del	DM, DI, SNHL, OA	A, Mo, Psy, B	30s	CA, BA, PVp, Pun	PV	-	N/P	N/P	-
11 ¹⁴	USA	20s/20s	C Het	c.320G>A, p.G107E c.1885C>T, p.R629W	DM, DI, SNHL, OA	A, Mo, S, B	20s	CA, BA, Po, PVp, Pun	-	-	N/P	N/P	-
12 ¹⁴	USA	10s/10s	C Het	c.740_741del, p.P247Cfs c.1243_1245del, p.V415del	DM, DI, SNHL, OA	A, Mo, M, PN, Psy, B	10s	CA, PVp, Pun	-	-	N/P	N/P	-
13 ¹⁴	USA	10s/20s	C Het	c.599T>C, p.L200P c.695G>C, p.R232P	DM, SNHL, OA	A, Sp, Psy, CD, B	20s	BA, Po, PVp, Pun†	Sub, PV	-	N/P	N/P	-
14 ¹⁴	USA	10s/10s	C Het	c.1251_1252delinsG, p.P417Lfs c.1885C>T, p.R629W	DM, DI, SNHL, OA	Hypor, Psy, B	10s	PVp, Pun	-	-	N/P	N/P	-
15 ¹⁷	Turkey	10s/10s	Het	c.1230_1233delCTCT, p.V412Sfs	OA, C	A, S, CD	10s	BA, Po, D	-	-	N/P	N/P	-
16	Italy	0s/20s	C Het	c.605A>G, p.E202G c.1628T>G, p.L543R	DM, OA	DN, B	30s	Po, PVp	-	-	N/P	N/P	-
17	Italy	0s/10s	C Het	c.409_424dup16, p.V142Gfs c.1628T>G, p.L543R	DM, DI, SNHL, OA	Psy, B	10s	Po, PVp	-	-	N/P	N/P	-

Table 1. Clinical, genetic, and neuroradiological data compiled from 17 WFS subjects.

Legend: **A** = ataxia and/or other cerebellar signs; **B** = bladder dysfunction; **BA** = brainstem atrophy; **C** = cataract; **CA** = cerebellar atrophy; **Cal** = callosal/pericallosal; **CD** = cognitive deficit; **Cer** = cerebellar white matter/peduncles; **C** Het = compound heterozygous; **D** = diffuse/confluent involvement of the centrum semiovale and/or peritrigonal white matter; **DCo** = diabetic coma; **DI** = diabetes insipidus; **DM** = diabetes mellitus; **DN** = diabetes neutrophy; **Het** = heterozygous; **Hom** = homozygous; **Hyperr** = hypereflexia; **Hypor** = hyporeflexia; **JxU** = juxtacortical/U-fiber; **LP** = lumbar puncture; **M** = migraine; **Mo** = other motor issues; **MS** = multiple selerosis; **N/A** = not available; **N/P** = not performed; **OA** = optic atrophy; **OCBs** = oligoclonal bands; **Pit** = absent/diminished posterior pituitary bright spot; **PN** = peripheral neuropathy; **Po** = pontine signal changes; **Psy** = psychiatric symptoms; **Pun** = punctate subcortical white matter foci typical of WFS; **PV** = periventricular; **PVp** = diffuse, bilateral signal changes in posterior horn periventricular white matter and/or optic radiations; **S** = seizures; **SC** = spinal cord; **SNHL** = sensorineural hearing loss; **Sp** = spasticity; **Sub** = subcortical; **WBCs** = white blood cells; † = focal lesion(s) ultimately categorized as intermediate (in between WFS and MS); ** = McDonald radiological criteria fulfilled.

MS-like lesion location or characteristic	Number of subjects (% of subjects with MS-like lesions)				
Subcortical	6 (86)				
Periventricular	4 (57)				
Juxtacortical/U-fiber	3 (43)				
Callosal/pericallosal	2 (29)				
Spinal cord (cervical)	2 (29)				
Cerebellar (white matter/peduncles)	1 (14)				
Gadolinium enhancement	3 (100)*				

Table 2. Distribution of MS plaque-like foci across the seven subjects in which these were identified.
*Only three radiologically MS-like subjects underwent post-contrast imaging.



- 487 Figure 1. Classical MRI features associated with WFS. A, Axial T2-weighted image showing
 488 bilateral pontine signal abnormality (subject #10). B, Axial T2-FLAIR image showing bilateral
- 489 symmetric posterior white matter abnormal signal as well as a punctate, round white matter signal
- 490 abnormality in the left frontal lobe (subject #14).



491 Figure 2. Patients with fulfilled or partially fulfilled McDonald criteria. A, B, and C represent

492 subject #2 (criteria fulfilled). A, Axial T2-FLAIR image showing multifocal periventricular, callosal,

493 and subcortical white matter lesions (arrows) with accompanying diffuse abnormal peritrigonal white

494 matter signal (circle). **B**, Post-gadolinium axial T1 image showing an enhancing callosal lesion. **C**,

495 Sagittal T2 image of the cervical and thoracic spinal cord showing a demyelinating lesion at the level
496 of C3. D, E, and F represent subject #1 (criteria partially fulfilled). D, Axial T2-FLAIR showing an

497 oval-shaped lesion in the left temporal subcortical white matter. **E**, Axial T2-FLAIR showing a

- 498 periventricular lesion around the frontal horn of the right lateral ventricle. F, Axial T2-FLAIR,
- 499 performed seven years after the first exam (**D**, **E**), showing new focal white matter lesions in the right
- 500 insula, right periventricular white matter, and along the posterior horn of the right lateral ventricle. G,
- 501 H, and I represent subject #3 (criteria fulfilled). G, Sagittal T2-FLAIR showing multifocal white
- 502 matter lesions perpendicular to the ventricular walls. **H**, Sagittal T2-FLAIR, performed four years
- 503 after initial MRI (G), demonstrating progression of the lesion burden in both the supra- and
- 504 infratentorial regions despite treatment with teriflunomide as of the first year in the four-year interval.
- 505 I, Axial T2 spinal cord MRI showing a white matter lesion located in the left posterior cord at the C3
- 506 level.



- 507 Figure 3. White matter abnormalities suggestive of an inflammatory process (A, B, C) or classified
- as intermediate (**D**) in four subjects with WFS. All images are axial T2-FLAIR. **A**, Elongated lesion
- located at the level of the anterior horn of the left lateral ventricle (subject #7). B, Small temporal
 periventricular lesion perpendicular to the right ventricular wall (subject #7). C, Small periventricular
- 510 periventricular lesion perpendicular to the right ventricular wall (subject #7). C, Small periventricular 511 lesion perpendicular to the right ventricular wall (subject #10). D, Left insular deep white matter
- 512 lesion classified as intermediate between suspicious for inflammatory process and typical for WFS
- 513 (subject #8).





